Cancer drug nivolumab takes on EBV-Linked tumors in new trial
NCT ID NCT03258567
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 10 times
Summary
This phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolumab every 4 weeks for up to 2 years. The study aims to see how many patients respond and to monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab
- What this could lead to
- If it works, this could offer a new treatment option for people with EBV-related cancers that haven't responded to standard therapy.
- What could go wrong
- This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. Nivolumab can cause immune-related side effects like inflammation in healthy organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC ACTIVE EPSTEIN-BARR VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can engineered immune cells tackle brain lymphoma?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a targeted pill boost Chemotherapy's punch against lymphoma?